Halozyme Therapeutics (NASDAQ:HALO) Releases FY25 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY25 earnings guidance on Wednesday. The company provided EPS guidance of $4.95-$5.35 for the period, compared to the consensus EPS estimate of $4.83. The company issued revenue guidance of $1.150-$1.225 billion, compared to the consensus revenue estimate of $1.16 billion. Halozyme Therapeutics also updated its FY 2024 guidance to 4.000-4.200 EPS.

Wall Street Analysts Forecast Growth

HALO has been the topic of several research reports. JMP Securities increased their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $58.00 to $62.00 in a report on Monday, October 7th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Piper Sandler increased their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. Finally, JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Stock Up 5.0 %

Shares of NASDAQ HALO opened at $53.76 on Thursday. The business has a 50-day moving average of $50.10 and a two-hundred day moving average of $54.00. The company has a market capitalization of $6.84 billion, a price-to-earnings ratio of 17.80, a price-to-earnings-growth ratio of 0.44 and a beta of 1.24. Halozyme Therapeutics has a 1 year low of $33.15 and a 1 year high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.70% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.